Production of fertile XY female animals from XY ES cells

Patent metadata

Field	Value
Publication number	US-9655351-B2
Application number	US-201615189767-A
Country	US
Kind code	B2
Filing date	Jun 22, 2016
Priority date	Jun 11, 2010
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

Methods and compositions are described for making phenotypically female fertile animals from XY donor cells and suitable host embryos. Culture media and methods are provided for maintaining XY donor cells in culture that after introduction into a host embryo and gestation in a suitable host will result in fertile XY female animals. Methods and compositions are described for making fertile female animals in an F0 generation from a donor XY cell and a host embryo, as are methods for making F1 progeny that are homozygous for a modification from a heterozygous F0 fertile male and a heterozygous F0 fertile female sibling.

First claim

We claim:

1. A method for making and breeding a fertile female XY mouse in an F0 generation, comprising:
(a) maintaining a donor XY mouse ES cell in a medium comprising:
(i) a base medium; and
(ii) supplements suitable for growing the mouse ES cells in culture and maintaining pluripotency,
wherein the donor XY mouse ES cell does not comprise a Tdy-negative sex reversal genetic modification, and wherein the base medium comprises sodium bicarbonate in a concentration of about 1.5-2.2 mg/mL, comprises sodium chloride, and has an osmolality of about 218-322 mOsm/kg;

(b) introducing a donor XY mouse ES cell from step (a) into a pre-morula stage host mouse embryo;
(c) introducing the host mouse embryo of step (b) into a recipient female mouse and gestating the host mouse embryo;
(d) obtaining an F0 XY mouse progeny comprising an F0 XY phenotypically female mouse, wherein upon attaining sexual maturity the F0 XY female mouse is fertile; and
(e) breeding the F0 XY fertile female mouse to produce progeny.

2. The method of claim 1 , wherein the base medium comprises about 2.2 mg/mL sodium bicarbonate and has an osmolality of about 218 mOsm/kg.

3. The method of claim 2 , wherein the base medium further comprises about 4.5 mg/mL glucose.

4. The method of claim 1 , wherein the base medium comprises about 1.5 mg/mL sodium bicarbonate and has an osmolality of about 261 mOsm/kg.

5. The method of claim 1 , wherein the base medium comprises about 1.5 mg/mL sodium bicarbonate and has an osmolality of about 294 mOsm/kg.

6. The method of claim 1 , wherein the base medium comprises about 2.2 mg/mL sodium bicarbonate and has an osmolality of about 270 mOsm/kg.

7. The method of claim 1 , wherein the base medium comprises about 2.2 mg/mL sodium bicarbonate and about 15.5 mg/mL glucose and has an osmolality of about 322 mOsm/kg.

8. The method of claim 1 , wherein the donor XY mouse ES cell comprises a genetic modification.

9. The method of claim 1 , wherein the maintaining the donor XY mouse ES cell in step (a) further comprises genetically modifying the donor XY mouse ES cell.

10. The method of claim 8 , wherein the genetic modification comprises one or more of a deletion in whole or in part of an endogenous nucleic acid sequence, a substitution of one or more nucleic acids, a replacement of an endogenous nucleic acid sequence with a heterologous nucleic acid sequence, a knockout, and a knock-in.

11. The method of claim 8 , wherein the genetic modification is a knockout of a STEAP2 gene.

12. The method of claim 8 , wherein the genetic modification is a deletion in whole or in part of an endogenous nucleic acid sequence.

13. The method of claim 8 , wherein the genetic modification is a substitution of one or more nucleic acids.

14. The method of claim 8 , wherein the genetic modification is replacement of an endogenous nucleic acid sequence with a heterologous nucleic acid sequence.

15. The method of claim 8 , wherein the genetic modification is a knockout.

16. The method of claim 8 , wherein the genetic modification is a knock-in.

17. The method of claim 8 , wherein the donor XY mouse ES cell is heterozygous for the genetic modification.

18. The method of claim 1 , wherein at least 34% of the F0 XY mouse progeny derived from the donor XY mouse ES cell are phenotypically female XY mice.

19. The method of claim 1 , wherein at least 15% of the F0 XY mouse progeny derived from the donor XY mouse ES cell are phenotypically female XY mice.

20. The method of claim 1 , wherein all of the females derived from the donor XY mouse ES cell in the F0 generation have a XY genotype.

21. The method of claim 1 , wherein the breeding comprises crossing the F0 XY fertile female mouse with a cohort F0 XY male mouse, wherein the F0 XY fertile female mouse and the F0 XY male mouse each is heterozygous for a genetic modification, and obtaining an F1 progeny mouse that is homozygous for the genetic modification.

22. A method for making and breeding a fertile female XY mouse in an F0 generation, comprising:
(a) maintaining a donor XY mouse ES cell in a medium comprising:
(i) a base medium; and
(ii) supplements suitable for growing the mouse ES cells in culture and maintaining pluripotency,

wherein the donor XY mouse ES cell does not comprise a Tdy-negative sex reversal genetic modification, and wherein the base medium comprises sodium bicarbonate in a concentration of about 17-30 mM and sodium chloride in a concentration of about 50-110 mM, and has an osmolality of about 218-322 mOsm/kg;
(b) introducing a donor XY mouse ES cell from step (a) into a pre-morula stage host mouse embryo;
(c) introducing the host mouse embryo of step (b) into a recipient female mouse and gestating the host mouse embryo;
(d) obtaining an F0 XY mouse progeny comprising an F0 XY phenotypically female mouse, wherein upon attaining sexual maturity the F0 XY female mouse is fertile; and
(e) breeding the F0 XY fertile female mouse to produce progeny.

23. The method of claim 22 , wherein the base medium comprises about 50 mM sodium chloride and about 26 mM sodium bicarbonate and has an osmolality of about 218 mOsm/kg.

24. The method of claim 23 , wherein the base medium further comprises about 25 mM glucose.

25. The method of claim 22 , wherein the base medium comprises about 87 mM sodium chloride and about 18 mM sodium bicarbonate and has an osmolality of about 261 mOsm/kg.

26. The method of claim 22 , wherein the base medium comprises about 110 mM sodium chloride and about 18 mM sodium bicarbonate and has an osmolality of about 294 mOsm/kg.

27. The method of claim 22 , wherein the base medium comprises about 87 mM sodium chloride and about 26 mM sodium bicarbonate and has an osmolality of about 270 mOsm/kg.

28. The method of claim 22 , wherein the base medium comprises about 87 mM sodium chloride, about 26 mM sodium bicarbonate, and about 86 mM glucose and has an osmolality of about 322 mOsm/kg.

29. The method of claim 22 , wherein the donor XY mouse ES cell comprises a genetic modification.

30. The method of claim 22 , wherein the maintaining the donor XY mouse ES cell in step (a) further comprises genetically modifying the donor XY mouse ES cell.

31. The method of claim 29 , wherein the genetic modification comprises one or more of a deletion in whole or in part of an endogenous nucleic acid sequence, a substitution of one or more nucleic acids, a replacement of an endogenous nucleic acid sequence with a heterologous nucleic acid sequence, a knockout, and a knock-in.

32. The method of claim 29 , wherein the genetic modification is a knockout of a STEAP2 gene.

33. The method of claim 29 , wherein the genetic modification is a deletion in whole or in part of an endogenous nucleic acid sequence.

34. The method of claim 29 , wherein the genetic modification is a substitution of one or more nucleic acids.

35. The method of claim 29 , wherein the genetic modification is replacement of an endogenous nucleic acid sequence with a heterologous nucleic acid sequence.

36. The method of claim 29 , wherein the genetic modification is a knockout.

37. The method of claim 29 , wherein the genetic modification is a knock-in.

38. The

Assignees

• Regeneron Pharma

Inventors

• Auerbach Wojtek
• Dechiara Thomas
• Poueymirou William
• Frendewey David
• Valenzuela David

Classifications

• A01K2217/054

  inducing loss of function · CPC title

• A01K2227/105

  Murine · CPC title

• A01K2267/0331

  Animal model for proliferative diseases · CPC title

• C12N5/0606

  Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696) · CPC title

• C12N2500/34

  Sugars · CPC title